{"id":60597,"date":"2025-01-09T04:03:58","date_gmt":"2025-01-09T03:03:58","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bonerge-announces-the-new-108-person-clinical-trial-exploring-skin-and-organ-anti-aging-innovations\/"},"modified":"2025-01-09T04:03:58","modified_gmt":"2025-01-09T03:03:58","slug":"bonerge-announces-the-new-108-person-clinical-trial-exploring-skin-and-organ-anti-aging-innovations","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bonerge-announces-the-new-108-person-clinical-trial-exploring-skin-and-organ-anti-aging-innovations\/","title":{"rendered":"Bonerge Announces the New 108 Person Clinical Trial: Exploring Skin and Organ Anti-Aging Innovations"},"content":{"rendered":"
\n

NEW YORK–(BUSINESS WIRE)–Bonerge announced the initiation of its clinical trial, focusing on Fisetin, Urolithin A, and Ergothioneine. Involving 108 participants, this trial aims to evaluate their combined effects on skin health and organ rejuvenation when taking orally, providing more reliable options for the market.<\/p>\n

<\/a>
<\/a><\/p>\n

\nSenolytics Research: Advancing the Science of Anti-Aging<\/b><\/p>\n

\nIn recent years, Senolytics research has advanced rapidly, with institutions like the Mayo Clinic and Wake Forest University at the forefront. Despite fruitful research, identifying optimal applications to translate Senolytics into market solutions remains crucial.<\/p>\n

\nIn October 2024, the Mayo Clinic published groundbreaking findings in Nature Aging, identifying 67 plasma proteins, with IL-23R emerging as a promising anti-aging biomarker1<\/sup>.<\/p>\n

\nThe study explored various promising Senolytics, including Fisetin, demonstrating a positive response in reducing senescence-related proteins and indicating potential for organ rejuvenation via senescent cell clearance2<\/sup>.<\/p>\n

\nThe concept of organ rejuvenation offering deeper insights into its systemic effects and guiding anti-aging strategies. Senolytics show strong potential for organ rejuvenation applications and promise broader future prospects.<\/p>\n

\nBonerge\u2019s Clinical Trial: Exploring Skin as the Key to Rejuvenation<\/b><\/p>\n

\nThe skin, the largest organ of the human body, is the most visible indicator of aging and a key target for anti-aging. Bonerge has launched a clinical trial focused on skin anti-aging, involving 108 participants.<\/p>\n

\nThe trial evaluates skin anti-aging effects by assessing factors like skin heme, skin inflammation, transepidermal water loss, wrinkles, skin elasticity, skin firmness, melanin levels, and skin tone. Spanning 56 days, it aligns with two skin regeneration cycles, providing a detailed analysis of these key skin health indicators.<\/p>\n

\nThree ingredients tested in the trail:<\/b><\/p>\n